GlassScriptPhysician profile
Ashley Henegar
NPI 1659623817
$9,507.19
in general payments reported to CMS, 2019-2025
48 companies · $2,460 in 2025
The $2,460 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $779 · 2022: $844 · 2023: $2,239 · 2024: $3,185 · 2025: $2,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,026 · Education: $1,060 · Long Term Medical Supply Or Device Loan: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,026.18 |
| Education | $1,059.86 |
| Long Term Medical Supply Or Device Loan | $797.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,592.02 | 2021-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $740.04 | 2022-2025 | Erleada, Imbruvica, Darzalex |
| Astellas Pharma US INC | $718.60 | 2021-2024 | Xospata, Xtandi, Padcev |
| Seagen INC. | $707.35 | 2021-2025 | Tukysa, Adcetris, Padcev |
| Pfizer INC. | $672.83 | 2023-2025 | |
| Eisai INC. | $490.22 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $431.87 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $402.56 | 2022-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $292.95 | 2021-2025 | Tagrisso, Enhertu |
| Regeneron Healthcare Solutions, INC. | $276.50 | 2023-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $262.85 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $260.19 | 2022-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $227.55 | 2021-2023 | Lumakras |
| Ipsen Biopharmaceuticals, INC | $211.51 | 2023-2025 | Onivyde, Tazverik |
| Glaxosmithkline, LLC. | $206.19 | 2022-2025 | Zejula, Jemperli, Ojjaara |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Henegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.